S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
Top-Rated Stocks  
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$46.41
-0.94 (-1.99%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$46.19
▼
$47.92
50-Day Range
$41.42
▼
$59.78
52-Week Range
$27.65
▼
$103.92
Volume
700,609 shs
Average Volume
1.16 million shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$99.60

Guardant Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
114.6% Upside
$99.60 Price Target
Short Interest
Bearish
4.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.31mentions of Guardant Health in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$162,094 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.39) to ($5.24) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

111th out of 1,034 stocks

Medical Laboratories Industry

4th out of 25 stocks

See Top Rated MarketRank™ Stocks Here
GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

December 2, 2022 | americanbankingnews.com
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by Brokerages
November 18, 2022 | benzinga.com
Guardant Health Recent Insider Activity
November 15, 2022 | benzinga.com
Guardant Health Unusual Options Activity
November 9, 2022 | finance.yahoo.com
Guardant Health Third Quarter 2022 Earnings: EPS Misses Expectations
November 7, 2022 | seekingalpha.com
Guardant: A Temporary Exemption From The Gene Testing Market New Paradigm
November 1, 2022 | finance.yahoo.com
Down More Than 50%: These 3 “Strong Buy” Stocks Are Too Cheap to Ignore
October 17, 2022 | forbes.com
Blood Test For Cancer Gives New Life To Guardant Health Shares
October 16, 2022 | seekingalpha.com
Guardant: Saving Lives One Blood Test At A Time
October 11, 2022 | seekingalpha.com
GH Guardant Health, Inc.
October 11, 2022 | health.usnews.com
East Jefferson General Hospital
October 10, 2022 | finance.yahoo.com
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
October 7, 2022 | finance.yahoo.com
Cancer-Detecting Blood Tests Behind Illumina’s $7.1 Billion Antitrust Battle Gain Ground
October 6, 2022 | finance.yahoo.com
Stephens Starts Coverage On This Precision Oncology Company With 66% Upside
October 6, 2022 | finance.yahoo.com
Why Guardant Health Topped the Market on Thursday
October 4, 2022 | nasdaq.com
GH Crosses Above Key Moving Average Level
September 13, 2022 | nasdaq.com
First Week of GH January 2025 Options Trading
September 9, 2022 | finance.yahoo.com
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
September 6, 2022 | finance.yahoo.com
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
September 2, 2022 | benzinga.com
What Are Whales Doing With Guardant Health
August 31, 2022 | tmcnet.com
Guardant Health Expands Strategic Collaboration With Merck KGaA,
August 31, 2022 | barrons.com
Premarket Movers: Chewy Cl A, HP, Guardant Health
August 31, 2022 | markets.businessinsider.com
Guardant Health Expands Collaboration With Merck KGaA
August 31, 2022 | finance.yahoo.com
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
August 30, 2022 | finance.yahoo.com
Can this early-cancer detection company beat out billion-dollar liquid biopsy players?
August 17, 2022 | uk.investing.com
SVP Of Guardant Health Makes $484K Sale
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
11/03/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GH
CUSIP
N/A
CIK
1576280
Web
www.guardanthealth.com
Phone
(855) 698-8887
Fax
888-974-4258
Employees
1,373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$99.60
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+114.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-405,670,000.00
Net Margins
-140.58%
Pretax Margin
-136.14%
Return on Equity
-145.58%
Return on Assets
-30.70%

Debt

Debt-to-Equity Ratio
6.82
Current Ratio
6.46
Quick Ratio
6.10

Sales & Book Value

Annual Sales
$373.65 million
Price / Sales
12.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.34 per share
Price / Book
7.32

Miscellaneous

Outstanding Shares
102,436,000
Free Float
96,392,000
Market Cap
$4.75 billion
Optionable
Not Optionable
Beta
0.64

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 43)
    Co-Founder, Co-CEO & Chairman
    Comp: $13.66k
  • Dr. AmirAli Talasaz Ph.D. (Age 42)
    Co-CEO & Director
    Comp: $13.27k
  • Mr. Michael Bell (Age 53)
    Chief Financial Officer
    Comp: $1.2M
  • Mr. John G. Saia (Age 49)
    Chief Legal Officer
    Comp: $641.22k
  • Dr. Craig Eagle M.D. (Age 55)
    Chief Medical Officer
    Comp: $2.88M
  • Mr. Christopher Freeman (Age 48)
    Chief Commercial Officer of Oncology Bus.
    Comp: $740.23k
  • Mr. Andy Ament
    Sr. VP of Operations
  • Darya Chudova
    Sr. VP of Technology
  • Mr. Kumud KaliaMr. Kumud Kalia
    Chief Information Officer
  • Ms. Jennifer Higgins
    VP of Public Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.

What is Guardant Health's stock price forecast for 2023?

15 brokers have issued 12-month price targets for Guardant Health's stock. Their GH share price forecasts range from $50.00 to $165.00. On average, they anticipate the company's share price to reach $99.60 in the next year. This suggests a possible upside of 114.6% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2022?

Guardant Health's stock was trading at $100.02 on January 1st, 2022. Since then, GH shares have decreased by 53.6% and is now trading at $46.41.
View the best growth stocks for 2022 here.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our GH earnings forecast.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) announced its earnings results on Thursday, November, 3rd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by $0.31. The firm earned $117.40 million during the quarter, compared to analyst estimates of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative trailing twelve-month return on equity of 145.58%.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $440.00 million-$450.00 million, compared to the consensus revenue estimate of $461.29 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.70%), Temasek Holdings Private Ltd (1.58%), Price T Rowe Associates Inc. MD (1.56%), Massachusetts Financial Services Co. MA (0.97%), Blue Water Life Science Advisors LP (0.96%) and Alliancebernstein L.P. (0.72%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $46.41.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $4.75 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.93) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 12/9/2022 by MarketBeat.com Staff